Systems biology of tumor dormancy: linking biology and mathematics on multiple scales to improve cancer therapy.

For many decades, it has been appreciated that tumor progression is not monotonic, and development of a cancer cell does not equate to inevitable cancer presentation in the clinic. Tumor progression is challenged by numerous intrinsic and extrinsic bottlenecks that can hold the tumor in dormant stages for prolonged periods. Given the complex, multiscale nature of these bottlenecks, the Center of Cancer Systems Biology organized a workshop on critical issues of systems biology of tumor dormancy. The program for the meeting this past July, chaired by N. Almog and H. Enderling, included discussions and interactive breakout sessions on regulation of tumor dormancy by angiogenesis, tumor-immune system interactions, cancer stem cell kinetics, and cell signaling pathways. Three important conclusions emerged from the meeting. The first was the urgent need to differentiate between tumor cell and tumor population dormancy of the primary tumor and metastatic deposits, the second was the continued need for interdisciplinary dialogs, and the third was the need to bring cross-scale mechanistic thinking to the field to achieve a more robust understanding of tumor dormancy and its clinical implications.

[1]  B. Thiers,et al.  Identification of cells initiating human melanomas , 2009 .

[2]  A. Harris,et al.  Notch3 signalling promotes tumour growth in colorectal cancer , 2011, The Journal of pathology.

[3]  P. Bragado,et al.  Computational identification of a p38SAPK-regulated transcription factor network required for tumor cell quiescence. , 2009, Cancer research.

[4]  P Hahnfeldt,et al.  Migration rules: tumours are conglomerates of self-metastases , 2009, British Journal of Cancer.

[5]  Lynn Hlatky,et al.  Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  J. Aguirre-Ghiso,et al.  Models, mechanisms and clinical evidence for cancer dormancy , 2007, Nature Reviews Cancer.

[7]  D. Felsher Reversing cancer from inside and out: oncogene addiction, cellular senescence, and the angiogenic switch. , 2008, Lymphatic research and biology.

[8]  F. Hodi,et al.  Tumor and Stem Cell Biology Cancer Research Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells , 2010 .

[9]  I. Screpanti,et al.  Cross-talk between tumor and endothelial cells involving the Notch3-Dll4 interaction marks escape from tumor dormancy. , 2009, Cancer research.

[10]  S. Indraccolo,et al.  Ligand-driven activation of the Notch pathway in T-all and solid tumors: Why Not(ch)? , 2010, Cell cycle.

[11]  B. Quesnel,et al.  In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors , 2010, Cancer Immunology, Immunotherapy.

[12]  P. Goss,et al.  Does tumour dormancy offer a therapeutic target? , 2010, Nature Reviews Cancer.

[13]  D. Felsher MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell-Intrinsic and Host-Dependent Mechanisms. , 2010, Genes & cancer.

[14]  K. Basso,et al.  Modulation of microRNA expression in human T-cell development: targeting of NOTCH3 by miR-150. , 2011, Blood.

[15]  Raghu Kalluri,et al.  Cancer without disease , 2004, Nature.

[16]  Jonathan W. Uhr,et al.  Controversies in clinical cancer dormancy , 2011, Proceedings of the National Academy of Sciences.

[17]  P. Hahnfeldt,et al.  Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. , 1999, Cancer research.

[18]  William C Hines,et al.  Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression , 2011, Nature Medicine.

[19]  R. Raychowdhury,et al.  Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. , 2009, Cancer research.

[20]  G. Basso,et al.  Notch3-mediated regulation of MKP-1 levels promotes survival of T acute lymphoblastic leukemia cells , 2011, Leukemia.

[21]  David Zurakowski,et al.  A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. , 2006, Journal of the National Cancer Institute.

[22]  M. Chaplain,et al.  Paradoxical dependencies of tumor dormancy and progression on basic cell kinetics. , 2009, Cancer research.

[23]  B. Quesnel,et al.  In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis. , 2004, Blood.

[24]  N. Almog Molecular mechanisms underlying tumor dormancy. , 2010, Cancer letters.

[25]  P. Bragado,et al.  ERK1/2 and p38α/β Signaling in Tumor Cell Quiescence: Opportunities to Control Dormant Residual Disease , 2011, Clinical Cancer Research.